The Verdict - Eli Lilly and Company (LLY)
Rating | Avoid / reduce at current prices |
Current price | ~$1,220 |
Our fair-value range | $750-$900/share |
Business quality | Average / mixed, risk-constrained - 3.55 / 5.00 |
Eli Lilly is an exceptional growth franchise, but the stock trades above the full core fair-value range and even above the report’s $1,156 bullish DCF outcome. The issue is valuation, not current execution, and the market leaves little room for policy or pricing disappointment.
What the market is betting on
Lilly’s growth engine is dominated by Mounjaro and Zepbound, which together produced 65% of first-half 2026 revenue. At roughly $1,220, the stock effectively prices an operating path at or above the report’s bull case: sustained high-teens free-cash-flow growth for a decade, operating margins above 50%, capex normalization, successful follow-on medicines, and no major incretin price-setting shock. That is a demanding setup because realized prices fell 13% in Q2 2026, including a 36% decline outside the United States.
What the filings actually show
The operating momentum is extraordinary, but pricing pressure, policy intervention, capital intensity, and rising litigation risk matter more at this valuation.
Q2 revenue rose 48% to $22.974B, driven by 60% volume growth while realized prices declined 13%.
H1 2026 revenue reached $42.773B, up 51%, with Mounjaro revenue up 106% and Zepbound up 60%.
Q2 gross margin reached 85.8%, and full-year performance-margin guidance increased to 49.0%-50.5%.
H1 free cash flow was approximately $10.764B, but heavy manufacturing investment and acquisitions continue absorbing substantial capital.
Total debt rose to $54.9B from $42.5B at year-end 2025, although leverage and interest coverage remain manageable.
Government pricing exposure is expanding, with Jardiance affected in 2026 and Trulicity and Verzenio selected for 2028.
Metric | Current | Prior basis |
Revenue growth | H1 2026 +51% | FY2025 +45% |
Gross margin | H1 2026 84.0% | FY2025 83.0% |
Free cash flow | H1 2026 $10.764B | FY2025 $8.972B |
Total debt | Jun. 2026 $54.9B | Dec. 2025 $42.5B |
Diluted shares | Q2 2026 893.7M | Q2 2025 899.8M |
Three ways this plays out
If things break down: The practical stress range is $550-$700/share if pricing intervention, competition, and patent erosion reduce normalized earnings power; the severe bear DCF is about $343.
Most likely: Core investable fair value is $750-$900/share, with the 10-year base DCF near $781 and the EV/EBITDA cross-check around $710-$862.
If the bulls are right: Conditional upside is $900-$1,200/share if Lilly sustains better than 25% growth, stabilizes realized pricing, scales orforglipron and retatrutide, and avoids incretin IRA selection.
What would change our mind
The share price falls toward or below the $825 core midpoint while operating momentum remains intact.
Realized-price declines narrow toward 5% or better while volume growth stays strong.
2027 guidance exceeds roughly $105B of revenue, leverage stabilizes, and free-cash-flow conversion improves above 70%.
This is the compressed view. The full deep-dive - DCF scenarios, the complete scorecard, earnings-quality checks, and every risk we flagged - is available to TradeOS members: Read the full LLY report ->
This newsletter is for informational and educational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. The analysis is based on public filings and involves estimates that may prove wrong. Do your own research and consider consulting a licensed financial advisor. The author may hold positions in securities mentioned